No Chart Data Available
No Record Found
No Record Found
Sector
PharmaceuticalsOpen
₹60Prev. Close
₹62.98Turnover(Lac.)
₹5.66Day's High
₹63.7Day's Low
₹6052 Week's High
₹70.1652 Week's Low
₹25.35Book Value
₹18.09Face Value
₹10Mkt Cap (₹ Cr.)
110.23P/E
114.51EPS
0.55Divi. Yield
0No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 9.95 | 8.1 | 8.1 | 8.1 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 7.59 | -0.75 | -0.9 | -0.86 |
Net Worth | 17.54 | 7.35 | 7.2 | 7.24 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2017 | Mar-2016 | Mar-2015 | Mar-2014 |
|---|---|---|---|---|
Revenue | 3.5 | 0.92 | 1.45 | 5.74 |
yoy growth (%) | 277.33 | -36.13 | -74.63 | -3.58 |
Raw materials | -2.84 | 0 | -0.32 | -4.24 |
As % of sales | 81.2 | 0 | 22.17 | 73.84 |
Employee costs | -0.21 | -0.23 | -0.06 | -0.33 |
| Y/e 31 Mar( In .Cr) | Mar-2017 | Mar-2016 | Mar-2015 | Mar-2014 |
|---|---|---|---|---|
Profit before tax | 0.2 | 0.13 | 0.08 | 0.6 |
Depreciation | -0.12 | -0.33 | -0.39 | -0.28 |
Tax paid | -0.05 | -0.03 | -0.06 | -0.19 |
Working capital | 1.37 | -1.5 | -0.84 | 0.27 |
Other operating items |
| Y/e 31 Mar | Mar-2017 | Mar-2016 | Mar-2015 | Mar-2014 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 277.33 | -36.13 | -74.63 | -3.58 |
Op profit growth | -53.77 | -18.59 | -45.17 | 8.52 |
EBIT growth | 50.64 | 47.78 | -85.1 | 11.11 |
Net profit growth | 53.57 | 427.68 | -95.52 | 10.19 |
| Particulars (Rupees in Crores.) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|---|
Gross Sales | 8.61 | 9.24 | 10.24 | 10.46 | 10.5 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 8.61 | 9.24 | 10.24 | 10.46 | 10.5 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 0.64 | 0.34 | 0.6 | 0.38 | 0.21 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,707.55 | 93.87 | 4,09,698.44 | 705.44 | 0.94 | 5,651.21 | 99.24 |
Divis Laboratories Ltd DIVISLAB | 6,172.7 | 65.18 | 1,63,865.79 | 696 | 0.49 | 2,660 | 578.26 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 4,079.3 | 64.69 | 1,38,062.05 | 597 | 0.15 | 2,707 | 249.82 |
Cipla Ltd CIPLA | 1,342.1 | 23.66 | 1,08,412.24 | 616.88 | 1.19 | 4,256.93 | 411.55 |
Dr Reddys Laboratories Ltd DRREDDY | 1,255.7 | 22.59 | 1,04,804.53 | 90.6 | 0.64 | 4,266.4 | 377.56 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
E D & Wholetime Director
VENKATESHWARLU PULLURU
Independent Non Exe. Director
JANARDHAN DAS KABRA
Non-Exec & Non-Independent Dir
Jivamohan Divakar Valluri
Independent Non Exe. Director
Monam Kapoor
Independent Non Exe. Director
Lakshman Samala
Non-Exec & Non-Independent Dir
GNANA PRAKASH GATTU
Independent Non Exe. Director
Mayuri Baidya
Company Sec. & Compli. Officer
Nishita Kalantri
Director
Sridevi Belide
4-4-231/1/2/ABC Inderbagh,
Sultan Bazar,
Telangana - 500095
Tel: 91-40-24757370
Website: http://www.trimurthidrugs.com
Email: info@trimurthidrugs.com
12-10-167,
Bharath Nagar,
Hyderbad - 500018
Tel: 91-040-23818475/76/2
Website: www.vccilindia.com
Email: info@vccilindia.com
Summary
Novelix Pharmaceuticals Limited was initially incorporated as Trimurthi Securities Limited on December 13, 1994. The name of the Company was changed from Trimurthi Securities Limited to Trimurthi Drug...
Read More
Reports by Trimurthi Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.